3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Neoplasms
1
Mycosis Fungoides
1
Lymphoproliferative Disorders
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Lymphatic Diseases
1
Immunoproliferative Disorders
1
Immune System Diseases
1
Interventions
Rituximab
4
Cyclophosphamide
4
ponatinib
2
Vorinostat
2
Vincristine
2
Prednisone
2
Etoposide
2
Doxorubicin
2
Brentuximab Vedotin
2
Bortezomib
2
tetulomab tetraxetan lu-177
1
pembrolizumab
1
ibrutinib
1
ibritumomab tiuxetan
1
fludarabine
1
durvalumab
1
cobomarsen
1
acalabrutinib
1
Melphalan
1
Lutetium
1
Lenalidomide
1
KW-2478
1
Imatinib Mesylate
1
Ifosfamide
1
Hsp90 inhibitor KU757
1
Cytarabine
1
Carmustine
1
Carboplatin
1
Bendamustine Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Immune System Diseases
×
cobomarsen
×
Clear all
NCT03713320
2022-04-08
SOLAR
miRagen Therapeutics, Inc.
Phase 2
Terminated
37 enrolled
23 charts